Whether hormone therapy raises your cardiovascular risk depends less on the hormone than on two things: how long ago you reached menopause and how the estrogen enters your body. In the Women's Health Initiative, women who started within 10 years of menopause showed no increase in coronary heart disease (Manson 2013). The same therapy started later looked different.
The two variables that decide most of the question
The old headline treated hormone therapy as a single risk. The evidence says otherwise. Two factors move the cardiovascular numbers more than the choice of estrogen itself: timing, meaning how close you are to menopause when you start, and route, meaning whether the estrogen is swallowed or absorbed through the skin. A woman of 52 starting a transdermal patch and a woman of 68 starting an oral pill are not running the same risk, even on the same hormone.
Timing: the window matters
The Women's Health Initiative enrolled women at a mean age of 63, more than a decade past menopause for many of them. In that population, oral conjugated estrogen plus a synthetic progestin produced about 8 more strokes per 10,000 women per year over placebo. That number is real, and it is where the fear came from.
The age-stratified reanalysis changed the picture. Women who began therapy within 10 years of menopause, or before age 60, did not show the increase in coronary heart disease seen in the older starters (Manson 2013). The ELITE trial tested this directly: estradiol slowed the progression of early atherosclerosis in women within 6 years of menopause but not in those more than 10 years out (Hodis 2016). This is the timing hypothesis, and it is why starting age is a central question in any cardiovascular assessment for hormone therapy.
Route: oral and transdermal are not the same
The way estrogen reaches the bloodstream changes its effect on clotting. Swallowed estrogen passes through the liver first and raises the production of clotting factors. Estradiol absorbed through the skin from a patch or gel largely skips that first pass, so it does not drive clotting the same way.
| Route | Venous clot risk | Notes |
|---|---|---|
| Oral estrogen (pill) | Higher than baseline | First-pass liver metabolism raises clotting factors; meta-analysis links oral therapy to roughly double the venous clot risk (Canonico 2008). |
| Transdermal estradiol (patch or gel) | Not raised at standard doses | Skips first-pass metabolism; standard doses show no measurable increase in venous clots (Canonico 2008). |
For a woman with clot or stroke risk factors, that difference is the reason the patch or gel is often preferred over the pill. The Menopause Society's 2022 position statement recommends transdermal estradiol for women at elevated risk of venous clots.
Baseline risk: your starting point still counts
Timing and route change the numbers, but they start from wherever your own cardiovascular risk already sits. A clinician weighs blood pressure, cholesterol, diabetes, smoking and family history alongside your age. The same framework that produces a 10-year cardiovascular risk estimate for statin decisions informs whether hormone therapy is a reasonable choice for you.
| Generally favorable | Needs closer review |
|---|---|
| Within 10 years of menopause or under 60 | More than 10 years past menopause or over 60 |
| No prior heart attack, stroke or venous clot | Prior venous clot, stroke or coronary disease |
| Blood pressure and cholesterol controlled | Uncontrolled high blood pressure |
| Transdermal route where clot risk is a concern | Active liver disease or a strong family clotting history |
What this does not mean
Hormone therapy is a treatment for menopausal symptoms, not a heart medication. The evidence that early, well-chosen therapy does not add cardiovascular risk is not evidence that it prevents heart disease, and the Menopause Society is explicit that hormone therapy should not be started for cardiovascular prevention alone. The 2022 statement makes that distinction plainly.
The November 2025 change to the boxed warning also did not erase every caution. The endometrial cancer warning remains on estrogen-alone products, and the cardiovascular data still separate early starters from late ones. A favorable profile is a reason to discuss hormone therapy with a clinician, not a guarantee.
The bottom line
Cardiovascular risk on hormone therapy turns on timing and route more than on the hormone. Started within 10 years of menopause, therapy did not raise coronary heart disease in the WHI reread. A transdermal patch or gel avoids the clotting effect that the oral route carries. Your own blood pressure, cholesterol and history set the baseline those two factors adjust. The assessment is individual, and it is worth having with someone who can see your full record.
This article is for education and is not a substitute for individual medical advice from your own clinician.